$Molecular predictors of response and survival in patients with relapsed/refractory acute myeloid leukemia following venetoclax plus hypomethylating agent therapy$

Molecular predictors of response and survival in patients with relapsed/refractory acute myeloid leukemia following venetoclax plus hypomethylating agent therapy

Not available.

Saved in:

Bibliographic Details
Main Authors:	Isla M. Johnson, Rimal Ilyas, Kristen McCullough, Aref Al-Kali, Hassan B. Alkhateeb, Kebede H. Begna, Abhishek Mangaonkar, Antoine Saliba, Mark R. Litzow, William Hogan, Mithun Shah, Mrinal M. Patnaik, Animesh Pardanani, Ayalew Tefferi, Naseema Gangat
Format:	Article
Language:	English
Published:	Ferrata Storti Foundation 2025-02-01
Series:	Haematologica
Online Access:	https://haematologica.org/article/view/11956
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Venetoclax schedule in AML: 7 vs 14 vs 21 vs 28 days
by: Naseema Gangat, et al.
Published: (2025-04-01)

<i>CSF3R</i> mutations and variants in myeloid neoplasms: associated phenotypes, co-mutations, and survival trends
by: Abiola Bolarinwa, et al.
Published: (2025-07-01)

Predictors of response to pacritinib therapy and survival among 60 Mayo Clinic patients with myelofibrosis treated outside of clinical trials
by: Maymona Abdelmagid, et al.
Published: (2025-03-01)

Momelotinib in JAK2 inhibitor-naïve myelofibrosis: pros and cons
by: Naseema Gangat, et al.
Published: (2025-05-01)

Cytogenetic abnormalities in polycythemia vera: phenotypic correlates and prognostic relevance in 669 informative cases
by: Moazah Iftikhar, et al.
Published: (2025-03-01)

RAS mutation identifies a poor prognostic molecular subtype of therapy-related myeloid neoplasm
by: Chung Hoow Kok, et al.
Published: (2025-08-01)

Prospective clinical trials of venetoclax and hypomethylating agents for relapsed BPDCN
by: Naveen Pemmaraju, et al.
Published: (2025-05-01)

Sodium-glucose co-transporter-2 inhibitor treatment-associated changes in hemoglobin level in anemic patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms
by: Ali Alsugair, et al.
Published: (2025-01-01)

Characteristics of patients with newly diagnosed acute myeloid leukemia not receiving treatment
by: Oudai Alkabbani, et al.
Published: (2025-07-01)

Basophilia and eosinophilia in primary myelofibrosis: phenotype, genotype, and prognostic correlates
by: Sarah Dingli, et al.
Published: (2025-04-01)

Outcomes With Venetoclax 50 mg, Hypomethylating Agents, and Voriconazole or Posaconazole in Acute Myeloid Leukemia
by: Kendall Diebold, et al.
Published: (2025-06-01)

Impact of monocytic differentiation on acute myeloid leukemia patients treated with venetoclax and hypomethylating agents
by: Dian Jin, et al.
Published: (2024-07-01)

Exposure-response analyses of venetoclax combined with hypomethylating agents in myelodysplastic syndromes: a retrospective study
by: Ji-Xin Tian, et al.
Published: (2025-07-01)

Venetoclax Combined with Hypomethylating Agents for Treatment-Naïve B/Myeloid Mixed Phenotype Acute Leukemia
by: Di Wu, et al.
Published: (2021-01-01)

Impact of KIT mutation on efficacy of venetoclax and hypomethylating agents in newly diagnosed acute myeloid leukemia
by: Wenxiu Shu, et al.
Published: (2025-05-01)

Real-life outcome after failure to venetoclax and hypomethylating-based therapy for acute myeloid leukemia
by: Carlos Jiménez-Vicente, et al.
Published: (2025-01-01)

Meta-analysis on the effectiveness and safety of venetoclax-based combination therapy with hypomethylation in acute myeloid leukemia
by: Yi Wang, et al.
Published: (2025-04-01)

Efficacy of the combination of venetoclax and hypomethylating agents in the treatment of patients with primary, relapsed and/or refractory acute myeloid leukemia
by: E. V. Usikova, et al.
Published: (2023-01-01)

Older Jehovah’s Witnesses with Acute Myeloid Leukemia: Hypomethylating Agents and Venetoclax as a Transfusion-Sparing Approach
by: Aditi Sharma, et al.
Published: (2025-06-01)

Validation of the 5th edition of the World Health Organization and International Consensus Classification guidelines for TP53-mutated myeloid neoplasm in an independent international cohort
by: Mithun Vinod Shah, et al.
Published: (2025-05-01)

Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patients
by: Christophe Willekens, et al.
Published: (2025-04-01)

Hypomethylating agents plus venetoclax for high-risk MDS and CMML as bridge therapy to transplant: a GESMD study
by: Ines Zugasti, et al.
Published: (2025-04-01)

Clinical Outcome and Molecular Profile in Patients with <i>DDX41</i> Mutation Hot-Spots
by: Nadia Toumeh, et al.
Published: (2025-05-01)

Selinexor in combination with venetoclax and decitabine in patients with refractory myelodysplastic syndrome previously exposed to hypomethylating agents: three case reports
by: Yunshuo Xiao, et al.
Published: (2024-12-01)

The efficacy of the combination of venetoclax and hypomethylating agents versus HAG agents in patients with acute myeloid leukemia: a retrospective study
by: Fei Xin, et al.
Published: (2024-12-01)

Immune-Mediated Autonomic Neuropathies following Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia
by: Abhishek Mangaonkar, et al.
Published: (2017-01-01)

Longer time from diagnosis to initiation of hypomethylating agents plus venetoclax for acute myeloid leukemia does not worsen survival: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)
by: Samuel J. Yates, et al.
Published: (2025-07-01)

Venetoclax and hypomethylating agents versus induction chemotherapy for newly diagnosed acute myeloid leukemia patients: a systematic review and meta-analysis
by: Yun Liu, et al.
Published: (2025-05-01)

Venetoclax in combination with hypomethylating agents in newly diagnosed and relapsed <i>CBF</i>β<i>::MYH11+</i> acute myeloid leukemia
by: Ziyu Feng, et al.
Published: (2025-02-01)

Significant prognostic improvement in elderly patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax: outcomes from a retrospective real-world analysis
by: Yi Chen, et al.
Published: (2025-12-01)

Prognostic value of measurable residual disease (MRD) for venetoclax in combination with hypomethylating agents in patients diagnosed with acute myeloid leukemia: validation of the ELN-2021 MRD recommendations
by: Carlos Jimenez-Vicente, et al.
Published: (2025-05-01)

Better Response and Prognosis of Venetoclax Plus Hypomethylating Agents Over Intensive Chemotherapy in Young Adults With Newly Diagnosed ASXL1‐Mutated Acute Myeloid Leukemia
by: Yiming Cai, et al.
Published: (2025-07-01)

REAL WORLD OUTCOMES OF HYPOMETHYLATING AGENTS AND VENETOCLAX COMBINATION THERAPY IN ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROME- SINGLE CENTER EXPERIENCE FROM A RESOURCE LIMITED COUNTRY
by: Maryam Khan
Published: (2025-07-01)

Hypomethylating Agents in Oncohematology
by: AD Shirin,, et al.
Published: (2016-10-01)

Newly diagnosed acute myeloid leukemia in unfit patients: 2026 treatment algorithms
by: Naseema Gangat, et al.
Published: (2025-08-01)

Neutrophil-to-lymphocyte ratio as a prognostic indicator of mortality in Polycythemia Vera: insights from a prospective cohort analysis
by: Tiziano Barbui, et al.
Published: (2024-11-01)

Hypomethylating agent versus venetoclax combination: an electronic health records-based target trial emulation among Asian elderly patients with newly diagnosed acute myeloid leukaemia in Hong Kong
by: Qiwen Fang, et al.
Published: (2025-07-01)

Extramedullary Involvement of Myelofibrosis in the Colon: A Case Report
by: Krystal Mills, et al.
Published: (2025-01-01)

Efficacy and prognostic analysis of venetoclax combined with hypomethylating agents for induction therapy in acute myeloid leukemia: a multi-center real-world study on indication-specific stratification, molecular markers, and hematologic toxicities
by: Leiming Xia, et al.
Published: (2025-07-01)

Venetoclax – The game-changer in hematology
by: Tanmoy Kumar Mandal, et al.
Published: (2020-01-01)